47 W. Watkins Mill Road
4 articles with Salubris Biotherapeutics
Salubris Biotherapeutics Announces Updated Phase 1b Data Demonstrating that JK07, the First Investigational Antibody Fusion Protein for Heart Failure, Resulted in Clinically Meaningful Improvements in Ejection Fraction
Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today announced positive interim data from the ongoing Phase 1b study of JK07 in heart failure with reduced ejection fraction (HFrEF).
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Salubris Biotherapeutics Announces New Pipeline Advancements and Appointment of Chief Medical Officer
Salubris Biotherapeutics, Inc. today reported new data from Cohort 2 of the ongoing Phase 1 study evaluating JK07, the Company’s lead drug candidate, for the treatment of heart failure with reduced ejection fraction (HFrEF).
Salubris Biotherapeutics Announces $32 Million Financing to Advance Novel Complex Biologics for Cardiovascular, Oncology, and Neurodegenerative Diseases
Salubris Biotherapeutics, Inc. today announced it received $32 million in financing from China-based Shenzhen Salubris Pharmaceuticals Co., Ltd.